Cell Biosciences, a Santa Clara, CA-based maker of life sciences instruments, supplies and software, said it has raised $20 million in a Series F venture round in connection with a $12 million acquisition of Toronto, Canada-based Convergent Bioscience. The investment was led by Essex Woodlands Health Ventures, and included existing investors such as The Wellcome Trust, Novo A/S, Domain Associates, Latterell Venture Partners, Royal Bank of Canada, The Vertical Group, and Lansing Brown Investments. Convergent, founded in 1995, has 45 employees.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
